Literature DB >> 19430447

Combine and conquer: handling biotech combination inventions in the wake of KSR.

Ha Kung Wong1, Dana Lau.   

Abstract

To what extent will KSR limit combination inventions in biotech?

Entities:  

Mesh:

Year:  2009        PMID: 19430447     DOI: 10.1038/nbt0509-446

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  1 in total

1.  A nail in the coffin for DNA sequence patents?

Authors:  Miles Yamanaka
Journal:  Nat Biotechnol       Date:  2008-10       Impact factor: 54.908

  1 in total
  2 in total

Review 1.  Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.

Authors:  Fangyu Lin; Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2013-07-30       Impact factor: 3.452

2.  The obviousness rejection as a barrier to biotech patent prosecution.

Authors:  Shyh-Jen Wang
Journal:  Nat Biotechnol       Date:  2009-12       Impact factor: 54.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.